CN117205312A - 治疗癌症的卡博替尼与阿特珠单抗组合 - Google Patents

治疗癌症的卡博替尼与阿特珠单抗组合 Download PDF

Info

Publication number
CN117205312A
CN117205312A CN202311144073.3A CN202311144073A CN117205312A CN 117205312 A CN117205312 A CN 117205312A CN 202311144073 A CN202311144073 A CN 202311144073A CN 117205312 A CN117205312 A CN 117205312A
Authority
CN
China
Prior art keywords
subjects
dose
study
treatment
alemtuzumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311144073.3A
Other languages
English (en)
Chinese (zh)
Inventor
G·施瓦布
C·谢佛德
C·海塞尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61569414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN117205312(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CN117205312A publication Critical patent/CN117205312A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202311144073.3A 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合 Pending CN117205312A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762448869P 2017-01-20 2017-01-20
US62/448,869 2017-01-20
US201762458447P 2017-02-13 2017-02-13
US62/458,447 2017-02-13
PCT/US2018/014523 WO2018136796A1 (en) 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer
CN201880013200.7A CN110352057A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880013200.7A Division CN110352057A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合

Publications (1)

Publication Number Publication Date
CN117205312A true CN117205312A (zh) 2023-12-12

Family

ID=61569414

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202311144073.3A Pending CN117205312A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN201880013200.7A Pending CN110352057A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144084.1A Pending CN117771363A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144074.8A Pending CN117205313A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201880013200.7A Pending CN110352057A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144084.1A Pending CN117771363A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144074.8A Pending CN117205313A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合

Country Status (15)

Country Link
US (2) US11198731B2 (https=)
EP (1) EP3570840B1 (https=)
JP (3) JP7222895B2 (https=)
KR (2) KR102610764B1 (https=)
CN (4) CN117205312A (https=)
AU (2) AU2018210397B2 (https=)
BR (1) BR112019015011A2 (https=)
CA (1) CA3049452A1 (https=)
ES (1) ES3031468T3 (https=)
IL (1) IL268138B (https=)
MA (1) MA47310A (https=)
MX (2) MX389966B (https=)
UA (1) UA126970C2 (https=)
WO (1) WO2018136796A1 (https=)
ZA (1) ZA201904652B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
US11198731B2 (en) * 2017-01-20 2021-12-14 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN117402114A (zh) 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
JP7653352B2 (ja) * 2018-09-05 2025-03-28 エクスプレステック、リミテッド、ライアビリティ、カンパニー 免疫グロブリンａ製剤
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
US12138351B2 (en) * 2020-04-14 2024-11-12 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
IL300151A (en) * 2020-07-31 2023-03-01 Exelixis Inc Combinations for cancer treatment
WO2022040555A2 (en) * 2020-08-21 2022-02-24 Exelixis, Inc. Method of treating cancer
WO2022197900A1 (en) * 2021-03-19 2022-09-22 Merck Sharp & Dohme Llc Methods for treating cancer with anti-ilt3 antibodies
US11620580B2 (en) * 2021-04-01 2023-04-04 Banjo Health Inc. Methods and systems for probabilistic filtering of candidate intervention representations
WO2024163400A1 (en) 2023-01-31 2024-08-08 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
EA030435B1 (ru) 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
WO2014165779A1 (en) * 2013-04-04 2014-10-09 Exelixis, Inc. Drug combinations to treat cancer
BR112016018450A2 (pt) * 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN109475545A (zh) * 2016-04-19 2019-03-15 埃克塞里艾克西斯公司 三阴性乳腺癌治疗方法
US11198731B2 (en) 2017-01-20 2021-12-14 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer

Also Published As

Publication number Publication date
ZA201904652B (en) 2024-11-27
JP2022121594A (ja) 2022-08-19
IL268138A (en) 2019-09-26
US20220056138A1 (en) 2022-02-24
AU2018210397A1 (en) 2019-07-25
MX2019008032A (es) 2019-12-16
CN117771363A (zh) 2024-03-29
ES3031468T3 (en) 2025-07-09
KR20190107103A (ko) 2019-09-18
US20190352403A1 (en) 2019-11-21
MX2022001718A (es) 2022-03-11
WO2018136796A1 (en) 2018-07-26
MA47310A (fr) 2019-11-27
EP3570840B1 (en) 2025-03-19
KR102610764B1 (ko) 2023-12-07
AU2018210397B2 (en) 2024-02-29
NZ755494A (en) 2025-06-27
BR112019015011A2 (pt) 2020-04-28
CN117205313A (zh) 2023-12-12
CA3049452A1 (en) 2018-07-26
UA126970C2 (uk) 2023-03-01
JP7222895B2 (ja) 2023-02-15
EP3570840A1 (en) 2019-11-27
IL268138B (en) 2022-08-01
MX389966B (es) 2025-03-20
AU2024203472A1 (en) 2024-06-13
JP2020514311A (ja) 2020-05-21
CN110352057A (zh) 2019-10-18
KR20230169458A (ko) 2023-12-15
US11198731B2 (en) 2021-12-14
JP2024019720A (ja) 2024-02-09

Similar Documents

Publication Publication Date Title
KR102610764B1 (ko) 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합
US12048698B2 (en) Treatment of HER2 positive cancers
Song et al. Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1
JP2026053570A (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
WO2022089377A1 (en) Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
HK40105136A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
HK40105135A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
HK40016051A (en) Combinations of cabozantinib and atezolizumab to treat cancer
JP2022550110A (ja) 連続的な治療設定における免疫チェックポイント阻害剤に対する患者の応答を高めるためのｆｇｆｒ遺伝子改変癌におけるｆｇｆｒ阻害剤の使用
EA041548B1 (ru) Способ лечения локальных поздних стадий солидных опухолей или метастатических солидных опухолей
HK40018507A (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
HK40018507B (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
NZ795674A (en) Combinations of cabozantinib and atezolizumab to treat cancer
Zeng et al. Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
Wei A Phase II, Single-center, Single-arm Clinical Trial on the Efficacy and Safety of Anti-PD-1 antibody (IBI308) Combined with Anlotinib for the Treatment of Recurrent or Advanced Endometrial Cancer
EA053269B1 (ru) Способы лечения рака желчных протоков с применением антитела к pd-l1 в сочетании с химиотерапией
EA044960B1 (ru) Лечение her2-положительных злокачественных новообразований

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105136

Country of ref document: HK